Literature DB >> 16735947

The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity.

Sonja Schrepfer1, Tobias Deuse, Thomas Münzel, Hansjörg Schäfer, Wilhelm Braendle, Hermann Reichenspurner.   

Abstract

OBJECTIVE: Current hormone therapy in postmenopausal women is associated with uterotrophic activity and cancer-promoting effects. In this experimental study, we compared the effects of the selective estrogen-receptor (ER) beta agonist biochanin A, and the selective ERalpha agonist ethinylestradiol, on the development of intimal hyperplasia after balloon injury and on uterus morphology.
DESIGN: Female F344 rats with or without prior ovariectomy were used for aortic denudations. Animals remained untreated or received oral biochanin A (100 mg/kg) or ethinylestradiol (100 microg/kg). After 14 days, aortas and uteri were harvested for histologic and immunohistochemical analyses. Computerized assessments of aortic adhesion molecule expression, and isometric relaxation experiments, and uteri were analyzed. In vitro studies with smooth muscle cells and endothelial cells were performed to further investigate the effects of hormone treatment on cell proliferation, migration and adhesion molecule expression.
RESULTS: Among untreated rats, ovariectomized animals tended to show greater neointimal hyperplasia and increased expression of the adhesion molecules 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). Biochanin A treatment reduced neointima formation, inhibited VCAM-1 up-regulation, and improved the vascular relaxation response. No effect was observed on uterus growth or histology. Ethinylestradiol also reduced aortic neointima formation and inhibited VCAM-1 up-regulation, but failed to improve endothelial function and significantly induced uterus growth. Both agents showed antiproliferative and weak antimigratory effects on smooth muscle cells, and reduced VCAM-1 expression on stimulated endothelial cells in vitro.
CONCLUSIONS: The ERbeta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. Because hormone therapy may have cancer-promoting side effects, administration of ERbeta-selective agents might be alternatively used to reduce the risk of cardiovascular disease in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735947     DOI: 10.1097/01.gme.0000185941.63497.10

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  10 in total

1.  Biochanin A attenuates zymosan-induced arthritis in mice similarly to 17-β estradiol: an alternative to hormone replacement therapy?

Authors:  Franciel Batista Felix; Jessica Maria Dantas Araújo; Elindayane Vieira de Souza; Vanessa Pinho; Enilton Aparecido Camargo; Cristiane Bani Corrêa; Renata Grespan
Journal:  Inflamm Res       Date:  2020-09-25       Impact factor: 4.575

2.  Loss-of-function deletion of the steroid receptor coactivator-1 gene in mice reduces estrogen effect on the vascular injury response.

Authors:  Yuhui Yuan; Jianming Xu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-04-19       Impact factor: 8.311

3.  Effects of an aqueous extract of dangguijagyagsan on serum lipid levels and blood flow improvement in ovariectomized rats.

Authors:  In Sil Park; Hye Won Lee; Jin Ah Ryuk; Byoung Seob Ko
Journal:  Evid Based Complement Alternat Med       Date:  2014-09-07       Impact factor: 2.629

4.  Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells.

Authors:  Mohieldin M Youssef; Mai F Tolba; Noha N Badawy; Andrew W Liu; Eman El-Ahwany; Amani E Khalifa; Suher Zada; Ashraf B Abdel-Naim
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

5.  Antiproliferative Activity of Combined Biochanin A and Ginsenoside Rh₂ on MDA-MB-231 and MCF-7 Human Breast Cancer Cells.

Authors:  Guixing Ren; Zhenxing Shi; Cong Teng; Yang Yao
Journal:  Molecules       Date:  2018-11-08       Impact factor: 4.411

6.  Biochanin A Attenuates Ovariectomy-Induced Cognition Deficit via Antioxidant Effects in Female Rats.

Authors:  Yanmeng Zhou; Bingbing Xu; Haiyang Yu; Wei Zhao; Xinxin Song; Yan Liu; Kainan Wang; Nikoli Peacher; Xiaomin Zhao; Han-Ting Zhang
Journal:  Front Pharmacol       Date:  2021-03-16       Impact factor: 5.810

7.  Heparin-Tagged PLA-PEG Copolymer-Encapsulated Biochanin A-Loaded (Mg/Al) LDH Nanoparticles Recommended for Non-Thrombogenic and Anti-Proliferative Stent Coating.

Authors:  Shivakalyani Adepu; Hongrong Luo; Seeram Ramakrishna
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

8.  The preventive effect of biochanin a on bone loss in ovariectomized rats: involvement in regulation of growth and activity of osteoblasts and osteoclasts.

Authors:  Shu-Jem Su; Yao-Tsung Yeh; Huey-Wen Shyu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-21       Impact factor: 2.629

9.  Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)alpha agonist and unaffected by an ER beta antagonist.

Authors:  Helen L Jeanes; Caroline Tabor; Darcey Black; Antwan Ederveen; Gillian A Gray
Journal:  J Endocrinol       Date:  2008-06       Impact factor: 4.286

10.  The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.

Authors:  Kumju Youn; Ji-Hyun Park; Jinhyuk Lee; Woo-Sik Jeong; Chi-Tang Ho; Mira Jun
Journal:  Nutrients       Date:  2016-10-14       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.